FDA approves first drug to delay onset of Type 1 diabetes
FILE, dmphoto/Getty Images(SILVER SPRING, Md.) -- For the first time, the U.S. Food and Drug Administration on Thursday approved a treatment that can delay the onset of Type 1 diabetes. Teplizumab, a monoclonal antibody that will be marketed under the brand name Tzield from pharmaceutical companies ProventionBio and Sanofi, is administered through intravenous infusion. The injection was shown in clinical trials to delay onset of insulin-dependent Type 1 diabetes for patients with autoantibody markers of early risk by over two years, with hopes for some that it can delay onset even longer. &quo...
Source: mycentraloregon.com